Related Experiment Videos
Borderline hypertension discovered during screening: effect of twelve months' treatment
Insights
Borderline hypertension, defined as diastolic blood pressure of 95 to 109 mm Hg, was more common in men. Active treatment significantly lowered blood pressure and improved ECG readings compared to placebo.
Area of Science:
- Cardiology
- Hypertension Research
- Preventive Medicine
Background:
- Borderline hypertension affects a significant portion of the population.
- Understanding the prevalence and impact of borderline hypertension is crucial for public health.
- Screening clinics provide valuable data on cardiovascular risk factors.
Purpose of the Study:
- To determine the frequency of borderline hypertension in a large cohort.
- To compare the prevalence of borderline hypertension between men and women.
- To evaluate the efficacy of active treatment versus placebo for borderline hypertension.
Main Methods:
- Cross-sectional analysis of 5,877 men and 1,125 women attending a screening clinic.
- Data collection on demographic factors, blood pressure, and electrocardiogram (ECG) readings.
- Randomized controlled trial comparing active treatment with placebo over 12 months.
Main Results:
- Borderline hypertension was more prevalent in men across all age groups.
- Active treatment resulted in a greater reduction in mean systolic and diastolic blood pressure compared to placebo.
- A significant decrease in selected ECG precordial lead voltages was observed in the active treatment group.
Conclusions:
- Men exhibit a higher frequency of borderline hypertension than women.
- Active treatment is effective in managing borderline hypertension and improving cardiovascular markers.
- Further research into long-term outcomes of borderline hypertension management is warranted.
Abstract:
The frequency of borderline hypertension (diastolic BP 95 to 109 mm Hg) is described in 5,877 men and 1,125 women attending a screening clinic. Borderline hypertension is more frequent in each 5-year age group in men than women. The results of the initial 12 months treatment show a greater fall in mean systolic and diastolic pressures in those on active treatment in comparison with placebo. Over the same 12 months the sum of selected ECG precordial lead voltages shows a significant fall in those on active treatment as compared with those on placebo.